疾病及发育中多肽:N-乙酰氨基半乳糖转移酶ppGalNAc-T的重要性

蛋白质的O-GalNAc糖基化是生物体内广泛存在的一种重要的蛋白质翻译后修饰,参与了众多生命活动过程。多肽:N-乙酰氨基半乳糖转移酶(ppGalNAc-T酶)是调控蛋白质O-GalNAc糖基化修饰的起始糖基转移酶,它催化N-乙酰氨基半乳糖(GalNAc)共价结合到蛋白质丝氨酸或苏氨酸的侧链羟基上,形成Tn糖链抗原结构。人体内ppGalNAc-T酶家族共有20个成员,各成员在不同的组织和细胞中的表达具有时空特异性,同时对其修饰的底物蛋白存在选择性。ppGalNAc-T酶的异常表达与组织器官发育,以及肿瘤、家族性钙质沉积、冠心病、阿尔兹海默症、先天性心脏病等复杂性疾病的发生发展密切相关。该文总结了近年来关于ppGalNAc-T酶在组织器官发育过程以及复杂性疾病发生发展中的研究概况,为深入理解ppGalNAc-T酶及O-糖基化的功能及其生物学意义提供参考。     

疾病及发育中多肽:N-乙酰氨基半乳糖转移酶ppGalNAc-T的重要性

蛋白质的O-GalNAc糖基化是生物体内广泛存在的一种重要的蛋白质翻译后修饰,参与了众多生命活动过程。多肽:N-乙酰氨基半乳糖转移酶(ppGalNAc-T酶)是调控蛋白质O-GalNAc糖基化修饰的起始糖基转移酶,它催化N-乙酰氨基半乳糖(GalNAc)共价结合到蛋白质丝氨酸或苏氨酸的侧链羟基上,形成Tn糖链抗原结构。人体内ppGalNAc-T酶家族共有20个成员,各成员在不同的组织和细胞中的表达具有时空特异性,同时对其修饰的底物蛋白存在选择性。ppGalNAc-T酶的异常表达与组织器官发育,以及肿瘤、家族性钙质沉积、冠心病、阿尔兹海默症、先天性心脏病等复杂性疾病的发生发展密切相关。该文总结了近年来关于ppGalNAc-T酶在组织器官发育过程以及复杂性疾病发生发展中的研究概况,为深入理解ppGalNAc-T酶和O-糖基化的功能及其生物学意义提供参考。     

UDP-GalNAc:多肽N-乙酰氨基半乳糖转移酶-14

UDP-GalNAc:多肽N-乙酰氨基半乳糖转移酶家族(简称GalNAc-T)是黏蛋白O-糖基化的起始酶,N-乙酰氨基半乳糖转移酶-14(GalNAc-T14)是该家族中最新发现的成员。近年来有人指出,O-糖基化可能与肿瘤的发生发展具有密切关系,因此对N-乙酰氨基半乳糖转移酶家族的研究也受到越来越多重视。本文主要综述了GalNAc-T14的命名、结构、分布、功能以及潜在的应用价值。     

黏蛋白型O-聚糖在人类肿瘤中的结构异常及生物学功能

黏蛋白是细胞表面的或分泌的、具有高度O-糖基化修饰的糖蛋白.在黏蛋白中,O-聚糖(O-glycan)是通过N-乙酰氨基半乳糖与丝氨酸或苏氨酸之间形成α连接,该结构即被称为黏蛋白型O-聚糖.黏蛋白型O-聚糖是由多肽∶N-乙酰氨基半乳糖转移酶(ppGalNAc-T)家族催化起始合成的,近年来,该酶的催化机制及结构特点已成为糖基转移酶研究的热点.在肿瘤中常常伴随着黏蛋白型O-聚糖结构上和数量上的改变,形成肿瘤特异聚糖结构(cancer-associated glycans),如肿瘤Tn和T抗原等.肿瘤特异聚糖使肿瘤细胞的抗原性和黏附能力发生改变,促进肿瘤细胞的恶性增生与转移.而这些肿瘤特异聚糖结构,也为肿瘤的诊断与抗肿瘤药物或疫苗开发提供了理论基础.     

黏蛋白型O-聚糖：结构、功能及与肿瘤的相关性

黏蛋白是细胞表面的或分泌的、具有高度O-糖基化修饰的糖蛋白。黏蛋白型O-聚糖是由多肽：N-乙酰氨基半乳糖转移酶（ppGalNAc-T）家族催化起始合成的,在肿瘤中常常伴随着黏蛋白型O-聚糖结构和数量上的改变,形成肿瘤特异聚糖结构（cancer-associated glycans）,如肿瘤Tn和T抗原等。肿瘤特异聚糖使肿瘤细胞的抗原性和黏附能力发生改变,促进肿瘤细胞的恶性增生与转移。而这些肿瘤特异聚糖结构,也为肿瘤的诊断与抗肿瘤药物或疫苗开发提供了理论基础。     

慢病毒介导的RNA干扰ppGalNAc-T2基因表达抑制Jurkat细胞增殖和迁移

在肿瘤中,黏蛋白O-糖基化有着重要的生物学功能.控制O-糖基化起始合成的是多肽∶N-乙酰氨基半乳糖转移酶家族,研究该酶家族对阐明O-糖基化在肿瘤中的作用机制有重要的意义.探讨了靶向干扰ppGalNAc-T2基因表达对白血病Jurkat细胞株增殖及迁移的影响.首先合成ppGalNAc-T2特异shRNA干扰及对照序列,将其连接至慢病毒干扰载体YH1;重组载体经双酶切、测序鉴定正确后与包装质粒共转染293T细胞,获得的病毒颗粒经过滤纯化后感染Jurkat细胞,流式细胞分选仪进行细胞分选以获得ppGalNAc-T2基因稳定干扰表达的Jurkat细胞,然后使用RT-PCR和Western blot方法对各组别细胞中ppGalNAc-T2基因表达情况进行分析,以确定ppGalNAc-T2基因表达被有效干扰;进一步利用MTT实验和Transwell实验分析ppGalNAc-T2基因干扰表达对Jurkat细胞增殖及迁移的影响.结果表明,成功构建了靶向干扰ppGalNAc-T2基因表达的慢病毒载体,感染Jurkat细胞后能稳定干扰ppGalNAc-T2基因表达.MTT和Transwell实验研究发现,下调ppGalNAc-T2基因表达对Jurkat细胞增殖和迁移有抑制作用.     

昆虫细胞内N-糖基化途径及人源化糖蛋白表达

虽然昆虫杆状病毒表达系统在蛋白表达领域得到了广泛的应用, 但由于不能表达复杂的末端唾液酸化的N-糖链, 使得该系统在生物制药行业的应用受到了很大的限制。通过比较哺乳动物细胞和昆虫细胞内糖基化途径可知, 其起始步骤一致, 之后再发生分化, 主要表现为3方面, 即昆虫细胞内缺乏哺乳动物细胞所具备的N-乙酰葡萄糖氨转移酶II、 半乳糖基转移酶/N-乙酰氨基半乳糖转移酶、α-2,3-唾液酸转移酶和α-2,6-唾液酸转移酶等延长N-糖链的糖基转移酶; 另外, 昆虫细胞内具有能够特异性地将蛋白质末端的N-乙酰氨基葡萄糖残基从GlcNAcMan3GlcNAc(±α3/6-Fuc)GlcNAc上切除的N-乙酰氨基葡萄糖苷酶及核心α-1,3-岩藻糖基转移酶。本文从上述异同出发, 综述了克服昆虫细胞内不能表达人源化糖蛋白这一缺陷所进行的N-糖基化途径的改造研究--主要集中在昆虫细胞内GlcNAcase的抑制和昆虫细胞内GnT2, GalT/ GalNAcT, ST3及ST6等基因的导入等方面, 结果表明经改造的昆虫细胞可表达人源化糖蛋白, 这将极大地拓宽昆虫杆状病毒表达系统的应用领域。本文还探讨了选择特殊细胞系及特殊培养条件以在昆虫细胞内表达唾液酸化蛋白的可行性。     

GALNT14与肿瘤

在过去的一个多世纪,许多肿瘤标志物被发现,其中包括多肽N-乙酰半乳糖胺基转移酶(polypeptide N-acetylgalactosaminyltransferase,ppGALNAc-T,简称GALNT)家族中的多个成员。GALNT家族是催化黏蛋白O-糖基化修饰的起始酶,其能够影响黏蛋白的O-糖基化,从而影响肿瘤细胞的发生、预后、增殖与迁移等。GALNT14是该家族中最新发现的成员之一,近年的研究发现,GALNT14在多种肿瘤中表达异常,并与肿瘤细胞的发生、侵袭、转移和凋亡等有关。本文主要对GALNT14蛋白的结构特点及其在肿瘤中的作用进行综述,为进一步研究GALNT14与肿瘤发病机制的关系以及作为潜在的药物靶点提供参考。     

综述: 糖基转移酶超家族在肿瘤转移中的作用

蛋白质的糖基化修饰主要包括N-连接糖基化、O-连接糖基化和糖基磷脂酰肌醇锚定连接．与核酸和蛋白质不同,糖链的合成过程并不遵循传统的基因信息传递的中心法则,主要由一系列催化糖苷键形成的糖基转移酶完成．异常糖基化修饰被认为与恶性肿瘤的发生发展和临床预后密切相关．研究表明,糖基转移酶的表达及其糖链结构的异常可通过调节肿瘤细胞与细胞外基质的相互作用,继而影响肿瘤转移的关键步骤,如上皮间质转化(E-钙黏着蛋白、N-钙黏着蛋白)、细胞的移动性(整合素β1和α5)、侵袭(基质金属蛋白酶MMPs)、浸润(唾液酸化Lewis抗原sLeX和sLeA)．本文主要就唾液酰基转移酶、岩藻糖基转移酶和N-乙酰氨基葡萄糖转移酶等三大糖基转移酶家族的结构和生物学功能及其在肿瘤转移中的作用作一综述,以期为肿瘤转移的预测和诊断提供新思路．     

糖基转移酶超家族在肿瘤转移中的作用

蛋白质的糖基化修饰主要包括N-连接糖基化、O-连接糖基化和糖基磷脂酰肌醇锚定连接.与核酸和蛋白质不同,糖链的合成过程并不遵循传统的基因信息传递的中心法则,主要由一系列催化糖苷键形成的糖基转移酶完成.异常糖基化修饰被认为与恶性肿瘤的发生发展和临床预后密切相关.研究表明,糖基转移酶的表达及其糖链结构的异常可通过调节肿瘤细胞与细胞外基质的相互作用,继而影响肿瘤转移的关键步骤,如上皮间质转化(E-钙黏着蛋白、N-钙黏着蛋白)、细胞的移动性(整合素β1和α5)、侵袭(基质金属蛋白酶MMPs)、浸润(唾液酸化Lewis抗原sLeX和sLeA).本文主要就唾液酰基转移酶、岩藻糖基转移酶和N-乙酰氨基葡萄糖转移酶等三大糖基转移酶家族的结构和生物学功能及其在肿瘤转移中的作用作一综述,以期为肿瘤转移的预测和诊断提供新思路.     

Characterization of ppGalNAc-T18, a member of the vertebrate-specific Y subfamily of UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases

The first step of mucin-type O-glycosylation is catalyzed by members of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (ppGalNAc-T; EC 2.4.1.41) family. Each member of this family has unique substrate specificity and expression profiles. In this report, we describe a new subfamily of ppGalNAc-Ts, designated the Y subfamily. The Y subfamily consists of four members, ppGalNAc-T8, -T9, -T17 and -T18, in which the conserved YDX(5)WGGENXE sequence in the Gal/GalNAc-T motif of ppGalNAc-Ts is mutated to LDX(5)YGGENXE. Phylogenetic analysis revealed that the Y subfamily members only exist in vertebrates. All four Y subfamily members lack in vitro GalNAc-transferase activity toward classical substrates possibly because of the UDP-GalNAc-binding pocket mutants. However, ppGalNAc-T18, the newly identified defining member, was localized in the endoplasmic reticulum rather than the Golgi apparatus in lung carcinoma cells. The knockdown of ppGalNAc-T18 altered cell morphology, proliferation potential and changed cell O-glycosylation. ppGalNAc-T18 can also modulate the in vitro GalNAc-transferase activity of ppGalNAc-T2 and -T10, suggesting that it may be a chaperone-like protein. These findings suggest that the new Y subfamily of ppGalNAc-Ts plays an important role in protein glycosylation; characterizing their functions will provide new insight into the role of ppGalNAc-Ts.     

TGF-β1 increases invasiveness of SW1990 cells through Rac1/ROS/NF-κB/IL-6/MMP-2

Post-translational acetylation is an important molecular regulatory mechanism affecting the biological activity of proteins. Polypeptide GalNAc transferases (ppGalNAc-Ts) are a family of enzymes that catalyze initiation of mucin-type O-glycosylation. All ppGalNAc-Ts in mammals are type II transmembrane proteins having a Golgi lumenal region that contains a catalytic domain with glycosyltransferase activity, and a C-terminal R-type (“ricin-like”) lectin domain. We investigated the effect of acetylation on catalytic activity of glycosyltransferase, and on fine carbohydrate-binding specificity of the R-type lectin domain of ppGalNAc-T2. Acetylation effect on ppGalNAc-T2 biological activity in vitro was studied using a purified human recombinant ppGalNAc-T2. Mass spectrometric analysis of acetylated ppGalNAc-T2 revealed seven acetylated amino acids (K103, S109, K111, K363, S373, K521, and S529); the first five are located in the catalytic domain. Specific glycosyltransferase activity of ppGalNAc-T2 was reduced 95% by acetylation. The last two amino acids, K521 and S529, are located in the lectin domain, and their acetylation results in alteration of the carbohydrate-binding ability of ppGalNAc-T2. Direct binding assays showed that acetylation of ppGalNAc-T2 enhances the recognition to αGalNAc residue of MUC1αGalNAc, while competitive assays showed that acetylation modifies the fine GalNAc-binding form of the lectin domain. Taken together, these findings clearly indicate that biological activity (catalytic capacity and glycan-binding ability) of ppGalNAc-T2 is regulated by acetylation.     

Inhibition of polypeptide N-acetyl-α-galactosaminyltransferases is an underlying mechanism of dietary polyphenols preventing colorectal tumorigenesis

Ellagitannin-derived ellagic acid (EA) and colonic metabolite urolithins are functional dietary ingredients for cancer prevention, but the underlying mechanism need elucidation. Mucin-type O-glycosylation, initiated by polypeptide N-acetyl-α-galactosaminyltransferases (ppGalNAc-Ts), fine-tunes multiple biological processes and is closely associated with cancer progression. Herein, we aim to explore how specific tannin-based polyphenols affect tumor behavior of colorectal cancer cells (CRC) by modulating O-glycosylation. Utilizing HPLC-based enzyme assay, we find urolithin D (UroD), EA and gallic acid (GA) potently inhibit ppGalNAc-Ts. In particular, UroD inhibits ppGalNAc-T2 through a peptide/protein-competitive manner with nanomolar affinity. Computational simulations combined with site-directed mutagenesis further support the inhibitors’ mode of action. Moreover, lectin analysis and metabolic labelling reveal that UroD can reduce cell O-glycans but not N-glycans. Transwell experiments prove that UroD inhibits migration and invasion of CRC cells. Our work proves that specific tannin-based polyphenols can potently inhibit ppGalNAc-Ts activity to reduce cell O-glycosylation and lead to lowering the migration and invasion of CRC cells, suggesting that disturbance of mucin-type O-glycosylation is an important mechanism for the function of dietary polyphenols.     

O-glycosylation in Toxoplasma gondii: identification and analysis of a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases

The initiation of mucin-type O-glycosylation is catalysed by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (EC 2.4.1.41). These enzymes are responsible for the transfer of N-acetylgalactosamine from the nucleotide sugar donor, UDP-GalNAc, to the hydroxyl group on specific serine or threonine residues in acceptor proteins. By screening a Toxoplasma gondii cDNA library, three distinct isoforms of the ppGalNAc-T gene family were cloned. Two additional isoforms were identified and partially cloned following analysis of the T. gondii genome sequence database. All of the cloned and identified ppGalNAc-T's are type II membrane proteins that share up to 50% amino acid sequence identity within the conserved catalytic domain. They each contain an N-terminal cytoplasmic domain, a hydrophobic transmembrane domain, and a lumenal domain; the latter consists of stem, catalytic, and lectin-like domains. Moreover, each of this ppGalNAc-T's contains important sequence motifs that are typical for this class of glycosyltransferases. These include a glycosyltransferase 1 motif containing the DXH sequence, a Gal/GalNAc-T motif, and the CLD and QXW sequence motifs located in alpha-, beta-, and gamma-repeats present within the lectin-like domain. The coding regions of T. gondii ppGalNAc-T1, -T2, and -T3 reside in multiple exons ranging in number from 6 to 10. Our results demonstrate that mucin-type O-glycosylation in T. gondii is catalysed by a multimember gene family, which is evolutionarily conserved from single-celled eukaryotes through nematodes and insects up to mammals. Taken together, this information creates the basis for future studies of the function of the ppGalNAc-T gene family in the pathobiology of this apicomplexan parasite.     

Polypeptide N-acetylgalactosaminyltransferase 18 non-catalytically regulates the ER homeostasis and O-glycosylation

Mucin-type O-glycosylation plays important roles in various biological processes. It is initiated by a family of 20 conserved UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts). Unlike most ppGalNAc-Ts localized to the Golgi apparatus, ppGalNAc-T18 is predominantly distributed on the endoplasmic reticulum (ER) and exhibits no ppGalNAc-T catalytic activity in vitro. Herein, we found that ppGalNAc-T18 silencing in cells decreased O-glycosylation levels and activated ER stress leading to apoptosis. After treatment with chemical chaperone 4-phenylbutyric acid (PBA) or forced expression of ppGalNAc-T18 in the ppGalNAc-T18 knockdown cell, these defects could be significantly alleviated, suggesting that ppGalNAc-T18 is important for ER homeostasis and protein O-glycosylation. Furthermore, we found that ppGalNAc-T18 exerts its functions in O-glycosylation and ER stress via a non-catalytic mechanism. These results reveal a novel molecular role of ppGalNAc-Ts that the ER-localized ppGalNAc-T18 could regulate the O-glycosylation and ER homeostasis in a non-catalytic manner.     

人ppGalNAc-T2的原核表达、纯化及其蓖麻蛋白样结构域的结构预测

多肽∶N乙酰氨基半乳糖转移酶(ppGalNAcT)是催化O糖基化的起始酶,在O聚糖的形成中起着关键的作用.为更好地研究该家族酶的结构与功能,采用PCR技术从pDONR201T2得到ppGalNAcT2全长编码序列,亚克隆至原核表达载体pGEX4T1,转化大肠杆菌BL21,获得相应表达产物,用谷胱甘肽S转移酶(GST)亲和层析柱进行纯化,并进行了Western印迹检测和初步的酶活测定.为进一步研究其功能还在结构研究上利用网络结构模拟SWISSMODEL服务器对ppGalNAcT2的蓖麻蛋白样结构域进行结构模拟.成功构建了原核表达载体pGEX4T1T2,获得有效表达和纯化,并初步鉴定了其活性,同时预测了其可能的三维结构和活性位点.     

Site directed processing: Role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2

Background

The assembly of Ser/Thr-linked O-glycans of mucins with core 2 structures is initiated by polypeptide GalNAc-transferase (ppGalNAc-T), followed by the action of core 1 β3-Gal-transferase (C1GalT) and core 2 β6-GlcNAc-transferase (C2GnT). β4-Gal-transferase (β4GalT) extends core 2 and forms the backbone structure for biologically important epitopes. O-glycan structures are often abnormal in chronic diseases. The goal of this work is to determine if the activity and specificity of these enzymes are directed by the sequences and glycosylation of substrates.

Methods

We studied the specificities of four enzymes that synthesize extended O-glycan core 2 using as acceptor substrates synthetic mucin derived peptides and glycopeptides, substituted with GalNAc or O-glycan core structures 1, 2, 3, 4 and 6.

Results

Specific Thr residues were found to be preferred sites for the addition of GalNAc, and Pro in the + 3 position was found to especially enhance primary glycosylation. An inverse relationship was found between the size of adjacent glycans and the rate of GalNAc addition. All four enzymes could distinguish between substrates having different amino acid sequences and O-glycosylated sites. A short glycopeptide Galβ1–3GalNAcα-TAGV was identified as an efficient C2GnT substrate.

Conclusions

The activities of four enzymes assembling the extended core 2 structure are affected by the amino acid sequence and presence of carbohydrates on nearby residues in acceptor glycopeptides. In particular, the sequences and O-glycosylation patterns direct the addition of the first and second sugar residues by ppGalNAc-T and C1GalT which act in a site directed fashion.

General significance

Knowledge of site directed processing enhances our understanding of the control of O-glycosylation in normal cells and in disease.     

Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat

The human glycoprotein MUC1 mucin plays a critical role in cancer progression. Breast, ovarian, and colon cancer cells often display unique cell-surface antigens corresponding to aberrantly glycosylated forms of the MUC1 tandem repeat. In this report, (15)N- and (13)C-labeled forms of a recombinant MUC1 construct containing five tandem repeats were used as substrates to define the order and kinetics of addition of N-acetylgalactosamine (GalNAc) moieties by a recombinant active form of the human enzyme UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase I (ppGalNAc-T1; residues 40-559). Heteronuclear NMR experiments were performed to assign resonances associated with the two serines (Ser5 and Ser15) and three threonines (Thr6, Thr14, and Thr19) present in the 20-residue long MUC1 repeat. The kinetics and order of addition of GalNAc moieties (Tn antigen) on the MUC1 construct by human ppGalNAc-T1 were subsequently dissected by NMR spectroscopy. Threonine 14 was shown to be rapidly glycosylated by ppGalNAc-T1 with an initial rate of 25 microM/min, followed by Thr6 (8.6 microM/min). The enzyme also modified Ser5 at a slower rate (1.7 microM/min), an event that started only after the glycosylation of Thr14 and Thr6 side chains was mostly completed. Ser15 and Thr19 remained unglycosylated by ppGalNAc-T1. Corresponding O-glycosylation sites within all five tandem repeats were simultaneously modified by ppGalNAc-T1, suggesting that each repeat behaves as an independent substrate unit. This study demonstrated that the hydroxyl oxygens of Thr14 and to a lesser extent Thr 6 represent the two dominant substrates modified by ppGalNAc-T1 within the context of a complex MUC1 peptide substrate. More importantly, the availability of defined isotopically labelled MUC1 glycopeptide substrates and the relative simplicity of their NMR spectra will facilitate the analysis of other transferases within the O-glycosylation pathways and the rational design of tumor-associated MUC1 antigens.     

UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker.

Mucin O-glycosylation is characterized in cancer by aberrant expression of immature carbohydrate structures (Tn, T, and sialyl-Tn antigens). The UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-T) family enzymes regulate the initial steps of mucin O-glycosylation and could be responsible for the altered glycosylation observed in cancer. Considering that we recently found the ppGalNAc-T6 mRNA expressed in breast carcinomas, we produced a highly specific monoclonal antibody (MAb T6.3) to assess the expression profile of ppGalNAc-T6 protein product in breast tissues. The expression of ppGalNAc-T6 by breast carcinoma cells was confirmed on MCF-7 and T47D cell lines. In formalin-fixed tissues, ppGalNAc-T6 expression was observed in 60/74 (81%) breast cancers, 21/23 (91.3%) adjacent ductal carcinoma in situ (DCIS), 4/20 benign breast lesions (2/2 sclerosing adenosis and 2/13 fibroadenoma), and in 0/5 normal breast samples. We observed a statistically significant association of ppGalNAc-T6 expression with T1 tumor stage. This fact, as well as the observation that ppGalNAc-T6 was strongly expressed in sclerosing adenosis and in most DCIS, suggests that ppGalNAc-T6 expression could be an early event during human breast carcinogenesis. Considering that an abnormal O-glycosylation greatly contributes to the phenotype and biology of breast cancer cells, ppGalNAc-T6 expression could provide new insights about breast cancer glycobiology.     

Mucin-type O-glycosylation in Mesocestoides vogae (syn. corti)

Protein glycosylation is an important post-translational modification underlying host-parasite interactions, which may determine the outcome of infection. Although Mesocestoides vogae represents an important model for investigating the various aspects of cestode biology, virtually no information is available about the structure and synthesis of glycans in this parasite. In this work, focused on the initiation pathway of mucin-type O-glycosylation in M. vogae, we characterized O-glycoproteins bearing the simple mucin-type cancer-associated Tn and sialyl-Tn antigens, and the expression and activity of ppGalNAc-T, the key enzyme responsible for the first step of mucin-type O-glycosylation. Using immunohistochemistry, Tn and sialyl-Tn antigens were detected mainly in the tegument (microtriches) and in parenchymal cells. Tn expression was also observed in lateral nerve cords. Both Tn and sialyl-Tn antigens were detected in in vitro cultured parasites. Based on their electrophoretic mobility, Tn- and sialyl-Tn-bearing glycoproteins from M. vogae were separated into several components of 22 to 60 kDa. The observation that Tn and sialyl-Tn glycoproteins remained in the 0.6N perchloric acid-soluble fraction suggested that they could be good candidates for characterizing mucin-type glycosylation in this parasite. O-glycoproteins were purified and initially characterized using a proteomic approach. Immunohistochemical analysis of the tissue distribution of ppGalNAc-T revealed that this enzyme is expressed in the sub-tegumental region and in the parenchyma of the parasite. In M. vogae cultured in vitro, ppGalNAc-T was mainly detected in the suckers. Using a panel of 8 acceptor substrate synthetic peptides, we found that M. vogae ppGalNAc-T preferentially glycosylate threonine residues, the best substrates being peptides derived from human mucin MUC1 and from Trypanosoma cruzi mucin. These results suggest that M. vogae might represent a useful model to study O-glycosylation, and provide new research avenues for future studies on the glycopathobiology of helminth parasites.